Patient Summit USA 2016

eyeforpharma 10 - 11 October 2016, Sonesta Philadelphia, USA.
The 13th annual Patient Summit USA 2016 is where patient-driven partnerships with stakeholders actually happen. This is not just a talking shop - be one of 300+ senior pharma executives, regulatory authorities, providers, payers, advocates and patients who plan to deliver sustainable solutions to the patient community.

Patient Centricity ...so what?

  • Streamline cultural change by setting a universal framework for patient centricity
  • Prove ROI-driven patient initiatives and get internal buy-in
  • Hear directly from patients and caregivers and mend their disconnect with the industry
  • Overcome roadblocks to advocacy and adherence with an enhanced focus on access programs
  • Navigate a complex regulatory environment while still promoting your patient initiatives

Turn profit-patient into patient-profit
Transforming your profit-patient model into a patient-profit system is one of the biggest shake-ups in pharma's history.

Many major brands are already in the process of creating and developing a new patient-centric approach, and introducing measures to reward staff against patient-oriented metrics.

What was once an 'if?' has become a 'when and how?'. But changing an engrained mind-set requires a collaborative effort; the more companies that encourage–and in some cases enforce–patient-centricity, the more widespread the buy-in will be.

'Profit' is still a valid talking point - it hasn't become a dirty word. What has changed is that it is now being seen as a natural by-product of putting patients first.

Now that patients are being almost universally regarded as pivotal to the sustained growth of pharma, the question turns back to: how will an inverted model still provide profit for pharma and key stakeholders?

The conference aims to help pharma stakeholders share views, and examine ways to put patients at the centre of evolving pharma business models, without damaging profits. Putting patients first needs to be attractive on both the humanistic and fiscal levels in order for patient centricity to thrive.

World Pharma News readers can benefit from an exclusive discount code, save €200 using World Pharma News unique code WorldPharma200

For further information, please visit:
http://www.eyeforpharma.com/patientusa/

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

Bayer and Nuvisan create new research unit in Berl…

Bayer AG today announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an internationa...

Novartis announces MET inhibitor capmatinib (INC28…

Novartis announced that the US Food and Drug Administration (FDA) accepted and granted Priority Review to capmatinib’s (INC280) New Drug Application (NDA). Capmatinib is ...

WHO, China leaders discuss next steps in battle ag…

The Director-General of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People's Republic of China in Beijing. They sh...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...

Can bilingualism protect the brain even with early…

A study by York University psychology researchers provides new evidence that bilingualism can delay symptoms of dementia. Alzheimer's disease is the most common form of d...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...